Citations

Mayo Clinic

Showing 10 of 108522 citations.

Deconvolution of the tumor-educated platelet transcriptome reveals activated platelet and inflammatory cell transcript signatures
Zhang, Ze-Yan , Ding, Yingwen , Graciani, Melanie, Sahimi, Ali , Chen, Ting , Li, Shuai , Wong, Kwok-Kin, Ramkhelawon, Bhama , Bhat, Krishna , Bhat, Krishna Pl, Karp, Jerome M. , Modrek, Aram Sandaldjian , Ezhilarasan, Ravesanker , Silvestro, Michele , Wong, Kwok‐Kin , Sulman, Erik P.

JCI Insight | August 27, 2024 | Volume: 9 | Issue: 19 | Pages: No page available

10.1172/jci.insight.178719 | PMID 39190500 Get It

Tumor-educated platelets (TEPs) are a potential method of liquid biopsy for the diagnosis and monitoring of cancer. However, the mechanism underlying tumor education of platelets is not known, and transcripts associated with TEPs are often not tumor-associated transcripts. We demonstrated that direct tumor transfer of transcripts to circulating platelets is an unlikely source of the TEP signal. We used CDSeq, a latent Dirichlet allocation algorithm, to deconvolute the TEP signal in blood samples from patients with glioblastoma. We demonstrated that a substantial proportion of transcripts in the platelet transcriptome are derived from nonplatelet cells, and the use of this algorithm allows the removal of contaminant transcripts. Furthermore, we used the results of this algorithm to demonstrate that TEPs represent a subset of more activated platelets, which also contain transcripts normally associated with nonplatelet inflammatory cells, suggesting that these inflammatory cells, possibly in the tumor microenvironment, transfer transcripts to platelets that are then found in circulation. Our analysis suggests a useful and efficient method of processing TEP transcriptomic data to enable the isolation of a unique TEP signal associated with specific tumors.
Perioperative Management and Outcomes after Endovascular Mechanical Thrombectomy in Patients with Submassive (Intermediate-Risk) Pulmonary Embolism: A Retrospective Observational Cohort Study
Merren, Michael P. , Padkins, Mitchell , Cajigas, Héctor , Neidert, Newton B. , Abcejo, Arnoley S. , Elmadhoun, Omar, Padkins, Mitchell R , Cajigas, Hector R , Abcejo, Arnoley

Healthcare | August 27, 2024 | Volume: 12 | Issue: 17 | Pages: 1714

10.3390/healthcare12171714 | PMID 39273738 Get It

Pulmonary embolism (PE) embodies a large healthcare burden globally and is the third leading cause of morbidity and mortality worldwide. Submassive (intermediate-risk) PE accounts for 40% of this burden. However, the optimal treatment pathway for this population remains complex and ill-defined. Catheter-directed interventions (CDIs) have shown promise in directly impacting morbidity and mortality while demonstrating a favorable success rate, safety profile, and decreased length of stay (LOS) in the intensive care unit and hospital. This retrospective review included 22 patients (50% female) with submassive PE who underwent mechanical thrombectomy (MT). A total of 45% had a contraindication to thrombolytics, the mean pulmonary embolism severity index was 127, 36% had saddle PE, the average decrease in mean pulmonary artery pressure (PAP) was 7.2 mmHg following MT, the average LOS was 6.9 days, the 30-day mortality rate was 9%, the major adverse event (MAE) rate was 9%, and the readmission rate was 13.6%. A total of 82% had successful removal of thrombus during MT with no major bleeding complications, intracranial hemorrhage events, or device-related deaths. Acknowledging the limitation of our small sample size, our data indicate that MT in the intermediate-high-risk submassive pulmonary embolism (PE) cohort resulted in a decreased hospital length of stay (LOS) and in-hospital mortality compared to standard anticoagulation therapy alone.
Full genomic sequence of the HLA‐DQB1*06:18:01 allele identified by next‐generation sequencing
Du, Zeying , Williams, C. D. H., Williams, Charles D, Du, Zeying , Williams, Charles D.

HLA | August 27, 2024 | Volume: 104 | Issue: 2 | Pages: No page available

10.1111/tan.15664 | PMID 39189318 Get It

Full‐length sequence of HLA‐DQB1*06:18:01 covers the 5′‐untranslated region (UTR), all introns and exons, and the 3’ UTR.
Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data Set
Elmunzer, B. Joseph , Zhang, Jingwen , Coté, Gregory A. , Wani, Sachin , Shah, Raj J. , Bang, Ji Young , Varadarajulu, Shyam , Singh, Vikesh K. , Khashab, Mouen A. , Kwon, Richard S. , Scheiman, James M., Keilin, Steven , Chak, Amitabh , Slivka, Adam, Mullady, Daniel , Kushnir, Vladimir , Buxbaum, James , Keswani, Rajesh N. , Gardner, Timothy B. , Forbes, Nauzer , Rastogi, Amit, Ross, Andrew S., Law, Joanna K. , Chen, Yen‐I , Smith, Zachary L. , Petersen, Bret T. , Wang, Andrew Y. , Saltzman, John R. , Spitzer, Rebecca L., Ordiah, Collins, Spino, Cathie , Foster, Lydia D. , Durkalski‐Mauldin, Valerie, Group*, on behalf of the SVI Study, Shah, Raj , Singh, Vikesh K , Kwon, Richard S , Willingham, Field F , Chak, Amitabh , Mullady, Daniel , Forbes, Nauzer , Ross, Andrew , Law, Joanna , Chen, Yen-I , Smith, Zachary L , Serrano, Jose , Petersen, Bret, Wang, Andrew Y , Saltzman, John R , Spino, Cathie , Foster, Lydia D , Edmundowicz, Steven A. , Willingham, Field F. , Papachristou, Georgios I. , Yachimski, Patrick , Barkun, Alan , Serrano, José , Group*, on behalf of the SVI Study

American Journal of Gastroenterology | August 27, 2024 | Volume: 120 | Issue: 4 | Pages: 811-815

10.14309/ajg.0000000000003052 | PMID 39207308 Get It

INTRODUCTION: Prophylactic pancreatic stent placement (PSP) is effective for preventing pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk cases, but the optimal technical approach to this intervention remains uncertain. METHODS: In this secondary analysis of 787 clinical trial patients who underwent successful stent placement, we studied the impact of (i) whether pancreatic wire access was achieved for the sole purpose of PSP or naturally during the conduct of the case, (ii) the amount of effort expended on PSP, (iii) stent length, (iv) stent diameter, and (v) guidewire caliber. We used logistic regression models to examine the adjusted association between each technical factor and post-ERCP pancreatitis (PEP). RESULTS: Ninety-one of the 787 patients experienced PEP. There was no clear association between PEP and whether pancreatic wire access was achieved for the sole purpose of PSP (vs occurring naturally; odds ratio [OR] 0.82, 95% confidence interval [CI] 0.37–1.84), whether substantial effort expended on stent placement (vs nonsubstantial effort; OR 1.58, 95% CI 0.73–3.45), stent length (>5 vs ≤5 cm; OR 1.01, 95% CI 0.63–1.61), stent diameter (≥5 vs <5 Fr; OR 1.13, 95% CI 0.65–1.96), or guidewire caliber (0.035 vs 0.025 in; 0.83, 95% CI 0.49–1.41). DISCUSSION: The 5 modifiable technical factors studied in this secondary analysis of large-scale randomized trial data did not appear to have a strong impact on the benefit of prophylactic PSP in preventing PEP after high-risk ERCP. Within the limitations of post hoc subgroup analysis, these findings may have important implications in procedural decision making and suggest that the benefit of PSP is robust to variations in technical approach.
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2 -Mutated Clonal Hematopoiesis
Ben-Crentsil, Nana Adjoa , Ismail, Wazim Mohammed , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall‐Fairbanks, Meghan C. , Fernandez, Jenna , Finke, Christy M. , Ibrahim, Mohammed L. , McGraw, Kathy L. , Wysota, Michael , Aldrich, Amy L. , Letson, Christopher T. , Traina, Joshua , McLemore, Amy F. , Droin, Nathalie , Sallman, David A. , Beg, Amer A. , Ma, Li , Gaspar‐Maia, Alexandre , Patnaik, Mrinal M. , Padron, Eric , Mohammed Ismail, Wazim , Balasis, Maria , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall-Fairbanks, Meghan C , Fernandez, Jenna , Lasho, Terra L , Finke, Christy M , Ibrahim, Mohammed L , McGraw, Kathy L , Wysota, Michael , Aldrich, Amy L , Ryder, Christopher B , Letson, Christopher T , Traina, Joshua , McLemore, Amy F , Droin, Nathalie , Shastri, Aditi , Yun, Seongseok , Solary, Eric , Sallman, David A , Beg, Amer A , Ma, Li , Gaspar-Maia, Alexandre , Patnaik, Mrinal , Padron, Eric , Balasis, Maria E. , Lasho, Terra L. , Yun, Seongseok , Solary, Éric

Cancer Discovery | August 27, 2024 | Volume: 14 | Issue: 12 | Pages: 2509-2531

10.1158/2159-8290.cd-24-0093 | PMID 39189614 Get It

Abstract TET2 mutations (mTET2) are common genetic events in myeloid malignancies and clonal hematopoiesis. These mutations arise in the founding clone and are implicated in many clinical sequelae associated with oncogenic feedforward inflammatory circuits. However, the direct downstream effector of mTET2 responsible for the potentiation of these inflammatory circuits is unknown. To address this, we performed scRNA-seq and scATAC-seq in patients with COVID-19 with and without TET2-mutated clonal hematopoiesis reasoning that inflammation from COVID-19 may highlight critical downstream transcriptional targets of mTET2. Using this approach, we identified metastasis-associated lung adenoma transcript 1 (MALAT1), a therapeutically tractable lncRNA, as a central downstream effector of mTET2 that is both necessary and sufficient to induce the oncogenic proinflammatory features of mTET2 in vivo. We also elucidate the mechanism by which mTET2 upregulate MALAT1 and describe an interaction between MALAT1 and p65, which leads to RNA “shielding” from protein phosphatase 2A dephosphorylation, thus preventing resolution of inflammatory signaling. Significance: This work identifies MALAT1 as a requisite downstream effector of oncogenic feedforward inflammatory circuits necessary for the development of TET2-mutated CH and fulminant myeloid malignancy. We elucidate a novel mechanism by which MALAT1 “shields” p65 from dephosphorylation to potentiate this circuit and nominate MALAT1 inhibition as a future therapeutic strategy.
Outcomes of Adults With Unrepaired Partial Anomalous Pulmonary Venous Return and Intact Atrial Septum
Egbe, Alexander C. , Younis, Ahmed , Ali, Ahmed E. , Karnakoti, Snigdha , Stephens, Elizabeth H. , Dearani, Joseph A. , François, Christopher J. , Connolly, Heidi M. , Dearani, Joseph A. , François, Christopher , Younis, Ahmed

Journal of the American Heart Association | August 27, 2024 | Volume: 13 | Issue: 17 | Pages: No page available

10.1161/jaha.124.036403 | PMID 39189474 Get It

Background The purpose of this study was to describe the correlates and outcomes in adults with unrepaired partial anomalous pulmonary venous return and intact atrial septum (PAPVR‐IAS). Methods and Results We identified adults with PAPVR‐IAS who received care at the Mayo Clinic, while those with unrepaired PAPVR‐IAS comprised the reference group. Clinical indices (New York Heart Association class, peak oxygen consumption, and NT‐proBNP [N‐terminal pro‐B‐type natriuretic peptide]) and echo‐derived right heart indices (right atrial [RA] volume, RA reservoir strain, right ventricular [RV] free wall strain, RV end‐diastolic area, and RV systolic pressure) were assessed at baseline and 3‐year and 5‐year follow‐up. There were 80 patients and 38 patients with unrepaired versus repaired PAPVR‐IAS, respectively. The clinical predictors of surgical repair were the number of anomalous veins, RA volume, and RV end‐diastolic area. The PAPVR‐IAS risk score, derived from these clinical predictors, was associated with surgical repair (adjusted odds ratio, 1.37 [95% CI, 1.24–1.65] per unit increase in risk score; area under the curve, 0.742). Among patients with unrepaired PAPVR‐IAS with 3‐year (n=73) and 5‐year follow‐up (n=36), there was no temporal change in clinical indices (New York Heart Association class, predicted peak oxygen consumption, and NT‐proBNP) and right heart indices (RA volume index, RA reservoir strain, RV end‐diastolic area index, RV free wall strain, and RV systolic pressure). Conclusions The PAPVR‐IAS risk score can be used to assess the odds of requiring surgical repair. Furthermore, there was no temporal deterioration in clinical and right heart indices during follow‐up in adults with unrepaired PAPVR‐IAS.
Laparoscopic Distal Pancreatectomy And Splenectomy for VIPoma
Sadek, Kareem , Vega, Viviana, Vega, Viviana , Stauffer, John

Videoscopy | August 27, 2024 | Volume: 34 | Issue: 1 | Pages: 1-2

10.1089/vor.2024.0018 Get It

Future Prospects of Metabolic and Bariatric Surgery: A Comprehensive Review
Perrotta, Gerardo , Betancourt, Richard S., Danaf, Jamil, Gajjar, Aryan , Tomey, Daniel , Marrero, Katie , Hage, Karl , Perrotta, Gerardo , Betancourt, Richard S , Tomey, Daniel , Ghanem, Omar M.

Healthcare | August 27, 2024 | Volume: 12 | Issue: 17 | Pages: 1707

10.3390/healthcare12171707 | PMID 39273731 Get It

Background: The field of metabolic and bariatric surgery (MBS) is currently an expanding surgical field with constant refinements in techniques, outcomes, indications, and objectives. MBS has been effectively applied across diverse patient demographics, including varying ages, genders, body mass indexes, and comorbidity statuses. Methods: We performed a comprehensive literature review of published retrospective cohort studies, meta-analyses, systematic reviews, and literature reviews from inception to 2024, reporting outcomes of MBS using databases such as PubMed, ScienceDirect, and Springer Link. Results: MBS is a safe and efficient therapeutic option for patients with obesity and associated medical conditions (mortality rate 0.03–0.2%; complication rates 0.4–1%). The favorable safety profile of MBS in the short-, mid-, and long-term offers the potential to treat patients with obesity and type 2 diabetes mellitus, immunosuppression, chronic anticoagulation, neoplastic disease, and end-organ failure without increased morbidity and mortality. Conclusions: In conclusion, the future of MBS lies in the ongoing innovation and adapted therapeutic strategies along with the integration of a variety of other techniques for managing obesity. Careful preoperative assessments, coupled with a multidisciplinary approach, remain essential to ensure optimal surgical outcomes and patient satisfaction after MBS.
Clinical Characteristics of Overweight Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)
Gong, Yuxin , Du, Fawang , Yao, Yu , Wang, Hanchao , Wang, Xiaochuan , Xiong, Wei , Wang, Qin , He, Gaoyan , Du, H D , Yang, Juan , Bauer, Brent A. , Wang, Zhongruo , Deng, Huojin , Zhu, Tao , Chen, Linlin , Du, Heng , Yang, Juan , Bauer, Brent A , Wang, Zhongruo , Deng, Huojin , Zhu, Tao , Gong, Yuxin

The Clinical Respiratory Journal | August 27, 2024 | Volume: 18 | Issue: 8 | Pages: No page available

10.1111/crj.70001 | PMID 39187923 Get It

ABSTRACTIntroductionLow body weight in patients with COPD is associated with a poor prognosis and more comorbidities. However, the impact of increased body weight in patients with COPD remains controversial. The aim of this study was to explore the clinical features of overweight patients with AECOPD.MethodsIn this multicenter cross‐sectional study, a total of 647 AECOPD patients were recruited. Finally, 269 normal weight and 162 overweight patients were included. Baseline characteristics and clinical and laboratory data were collected. The least absolute shrinkage and selection operator (LASSO) regression was performed to determine potential features, which were substituted into binary logistic regression to reveal overweight‐associated clinical features. The nomogram and its associated curves were established to visualize and verify the logistic regression model.ResultsSix potential overweight‐associated variables were selected by LASSO regression. Subsequently, a binary logistic regression model identified that the rates of type 2 diabetes (T2DM) and hypertension and levels of lymphocytes (LYM)%, and alanine aminotransferase (ALT) were independent variables of overweight in AECOPD patients. The C‐index and AUC of the ROC curve of the nomogram were 0.671 and 0.666, respectively. The DCA curve revealed that the nomogram had more clinical benefits if the threshold was at a range of 0.22~0.78.ConclusionsCollectively, we revealed that T2DM and hypertension were more common, and LYM% and ALT were higher in AECOPD patients with overweight than those with normal weight. The result suggests that AECOPD patients with overweight are at risk for additional comorbidities, potentially leading to worse outcomes.
CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
Kumar, Emil , Korfi, Koorosh , Close, Karina , Leukam, Michael , Ansell, Stephen M. , Scott, Jessica, Clear, Andrew , Siebert, R., Peck, Barrie , Calaminici, Maria , Smith, Sonali M. , Novak, Anne J. , Kumar, Emil Arjun , Ansell, Stephen M , Fitzgibbon, Jude , Okosun, Jessica , Bewicke‐Copley, Findlay , Heward, James A. , Witzig, Thomas E. , Scott, Jessica, Efeyan, Alejo , Green, Michael Richard , Siebert, Reiner, Wang, Jun , Fitzgibbon, Jude

British Journal of Haematology | August 27, 2024 | Volume: 205 | Issue: 5 | Pages: 1804-1809

10.1111/bjh.19671 | PMID 39188028 Get It

SummaryDespite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2‐mutant FL. Here we examined whether gene mutation status predicts response to clinical mTOR inhibitors (mTORi) in FL, by performing targeted mutational profiling of biopsies from 21 relapsed/refractory FL patients treated with mTORi everolimus or temsirolimus within clinical trials. We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi‐responders, and describe distinct transcriptional characteristics and co‐occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBPHAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL.